PTAB: Inadvertent Mistake in Analysis of Experimental Data that Substantially Impacts Proceeding Cannot be Corrected

Oct 6, 2020

Reading Time : 2 min

Petitioner Sweegen, Inc. filed a petition for post grant review (PGR) of a patent covering a method of making a certain chemical compound. Petitioner argued that the claims were anticipated by an example in a prior art reference. To support its anticipation argument, Petitioner commissioned a bioanalytical chemistry laboratory to replicate that example. Based on the testing results, Petitioner submitted two declarations and argued that performing the example in that reference would have necessarily produced a certain product. Almost a month after Petitioner filed the exhibits, one of the laboratory’s employees discovered that the test results “inadvertently linked the tables to the incorrect data cells.” The correct results showed that more than twice the reported amount of the compound was actually produced in the reaction. Petitioner filed a motion to correct the error. Patent Owner opposed the motion and contended that the “proposed changes [would] have a substantial impact on the[] proceedings.”

The board acknowledged that clerical mistakes may be corrected as long as they do not sacrifice the notice function of a petition. The board considers several non-exclusive factors to determine whether to allow correction. Here, the board first found that the nature of the error was “substantial because Petitioner [sought] to change the data in three tables.” Even if the errors in the original report resulted from a clerical error, the proposed changes were “not mere clerical errors that may be corrected under Rule 104(c).” This factor weighed strongly in Patent Owner’s favor. Second, the board found that although there was some delay between discovery of the error and bringing it to the board’s attention, the delay was not unreasonable. Thus this second factor was neutral. Third, the board found that since the proposed changes were substantive, it would be prejudicial to force the Patent Owner to alter its arguments to account for the corrected data. Finally, the board found that the corrections would have a significant impact on the proceeding because they would “improv[e] Petitioner’s anticipation argument.” The third and fourth factors weighed heavily in Patent Owner’s favor. As a whole, the factors weighed in favor of Patent Owner and the board denied Petitioner’s motion.

Practice Tip: Petitioners should ensure that all supporting documents are correct before submitting the petition. A petitioner may not be permitted to correct clerical and typographical errors in its petition and supporting documents if the changes would require substantive alterations to the petitioner’s evidence or argument.

Sweegen, Inc. v. Purcircle SDN BDH, PGR2020-00070, Paper 9 (PTAB Sept. 22, 2020).

Share This Insight

Previous Entries

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

IP Newsflash

August 29, 2025

In a recent order addressing four IPR proceedings, the PTAB exercised its inherent authority under 37 C.F.R. § 42.5(a) to sua sponte authorize post-hearing discovery on a potentially dispositive privity issue. The order followed a Director review decision that vacated and remanded earlier IPRs involving the same parties, patent family, and privity issue. 

...

Read More

IP Newsflash

August 29, 2025

The Patent Trial and Appeal Board denied institution of an inter partes review petition in part because it determined that a patent reference was not prior art under the common ownership exception of pre-AIA 35 U.S.C. § 103(c)(1).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.